Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
Tramadol vs ACEPHEN
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Tramadol is a centrally acting synthetic opioid analgesic that binds to μ-opioid receptors and inhibits the reuptake of norepinephrine and serotonin, modulating pain transmission.
ACEPHEN (acetaminophen) is a para-aminophenol derivative with analgesic and antipyretic activity. Its mechanism involves inhibition of cyclooxygenase (COX) enzymes in the central nervous system, particularly COX-2, reducing prostaglandin synthesis. It has weak peripheral COX inhibition and minimal anti-inflammatory effect.
Moderate to moderately severe pain (FDA-approved),Chronic pain (off-label),Restless legs syndrome (off-label),Premature ejaculation (off-label),Osteoarthritis pain (off-label)
Mild to moderate pain,Fever
50-100 mg orally every 4-6 hours as needed for pain; maximum 400 mg/day. For moderate to severe pain, 50-100 mg IV or IM every 4-6 hours; maximum 600 mg/day.
325-650 mg orally every 4-6 hours as needed; maximum 4 g/day.
Terminal elimination half-life: approximately 6.3 hours (range 5-9 hours) for tramadol; active metabolite M1 has half-life ~7-9 hours. Clinically, dosing interval is typically every 4-6 hours.
Terminal elimination half-life: 1.0-1.5 hours in adults with normal renal function. Prolonged to 2-5 hours in hepatic impairment or elderly; requires dose adjustment in severe hepatic disease.
Hepatic via CYP2D6 and CYP3A4 to active metabolite O-desmethyltramadol (M1) and other inactive metabolites; undergoes conjugation.
Acetaminophen is primarily metabolized in the liver via glucuronidation (UGT1A1, UGT1A6, UGT1A9) and sulfation (SULT1A1, SULT1A3). A minor fraction is oxidized by cytochrome P450 enzymes (CYP2E1, CYP1A2, CYP3A4) to a reactive toxic metabolite (NAPQI), which is normally detoxified by conjugation with glutathione.
Primarily renal (90%): ~30% as unchanged drug, ~60% as metabolites. Biliary/fecal: ~10%.
Renal: 90-95% as unchanged drug; tubular secretion and glomerular filtration. Biliary/fecal: <5%.
Approximately 20% bound to plasma proteins (primarily albumin).
Approximately 10-20% bound to serum albumin; extensive tissue binding.
Approximately 2.6-3.0 L/kg (306-350 L for a 70 kg adult), indicating extensive tissue distribution.
Apparent Vd: 0.5-0.7 L/kg (30-40 L in a 70 kg adult). Distributions into CSF and breast milk.
Oral: approximately 70-75% (high first-pass metabolism). Rectal: similar to oral. Intramuscular: 100% (relative to IV).
Oral: 85-90% (first-pass metabolism minimal). Rectal: approximately 70-80% of oral bioavailability.
Cr Cl 30-59 m L/min: extend dosing interval to every 12 hours. Cr Cl <30 m L/min: extend interval to every 12 hours and consider max dose 200 mg/day. Hemodialysis: administer dose after dialysis, with same interval adjustments.
GFR 10-50 m L/min: 650 mg every 6 hours; GFR <10 m L/min: 650 mg every 8 hours.
Child-Pugh Class A (mild): 50 mg every 12 hours. Child-Pugh Class B (moderate): 50 mg every 12 hours. Child-Pugh Class C (severe): not recommended.
Child-Pugh Class A: no adjustment; Child-Pugh Class B: maximum 2 g/day; Child-Pugh Class C: maximum 1 g/day.
Age ≥16 years: same as adult dosing. Age 12-15 years: 50-100 mg orally every 4-6 hours; max 400 mg/day. For children <12 years: not recommended.
10-15 mg/kg/dose orally every 4-6 hours; maximum 75 mg/kg/day or 4 g/day, whichever is less.
Initiate at 25 mg orally every 6 hours as needed; titrate cautiously to 50 mg every 6 hours; max 300 mg/day. Consider creatinine clearance for dose adjustments.
Start at lowest effective dose (325 mg every 6 hours); avoid exceeding 3 g/day unless closely monitored.
Risk of addiction, abuse, and misuse; life-threatening respiratory depression; accidental ingestion; neonatal opioid withdrawal syndrome; risks from concomitant use with benzodiazepines or other CNS depressants; interactions with drugs affecting CYP450 isoenzymes; risk of serotonin syndrome; risk of seizures; risk of suicide in patients with depression.
Acetaminophen has been associated with cases of acute liver failure, at times resulting in liver transplant and death. Most of the cases of liver injury are associated with the use of acetaminophen at doses that exceed 4,000 milligrams per day, and often involve more than one acetaminophen-containing product.
Respiratory depression; seizures; serotonin syndrome; suicide risk; adrenal insufficiency; severe hypotension; use in renal/hepatic impairment; anaphylaxis; use with MAOIs; use in pregnancy (neonatal withdrawal); use in breastfeeding.
Risk of severe liver injury with doses >4000 mg/day; use caution with hepatic impairment, chronic alcoholism, malnutrition, or concomitant hepatotoxic drugs; avoid exceeding recommended dose; limit use to 10 days for pain or 3 days for fever unless directed by physician; serious skin reactions (Stevens-Johnson syndrome, toxic epidermal necrolysis) have occurred.
Hypersensitivity; concomitant use of MAOIs or within 14 days; significant respiratory depression; acute or severe bronchial asthma; gastrointestinal obstruction; use in children <12 years for post-tonsillectomy/adenoidectomy pain.
Hypersensitivity to acetaminophen or any component of the formulation; severe hepatic impairment or active liver disease.
No significant food interactions. Grapefruit juice does not substantially affect tramadol metabolism. Avoid alcohol entirely due to additive CNS depression and increased risk of hepatotoxicity. St. John's Wort may reduce tramadol efficacy by inducing CYP3A4 and CYP2D6. High-fat meals may delay absorption but do not significantly affect overall exposure; take extended-release tablets consistently with or without food.
Alcohol: increased risk of hepatotoxicity. Avoid concurrent use. Food: no significant interaction, but taking with food may reduce minor gastrointestinal irritation.
First trimester: Limited human data; animal studies show no clear teratogenicity at therapeutic doses but increased risk of neural tube defects at high doses. Second and third trimesters: Risk of neonatal respiratory depression, withdrawal syndrome, and reduced fetal growth with chronic use. Avoid or use lowest effective dose.
Pregnancy Category C. First trimester: potential risk of neural tube defects and orofacial clefts (limited human data, animal studies show embryotoxicity). Second and third trimesters: NSAID exposure associated with oligohydramnios, premature ductus arteriosus constriction, and fetal renal impairment. Avoid in third trimester.
Tramadol is excreted into breast milk; relative infant dose estimated at 0.1-3.1% of maternal weight-adjusted dose. M/P ratio approximately 1.3. Monitor infant for drowsiness, feeding difficulties, and constipation. Avoid in mothers with CYP2D6 ultra-rapid metabolism due to increased opioid exposure.
Excreted into breast milk in low concentrations (M/P ratio approximately 0.10). Considered compatible with breastfeeding; however, use lowest effective dose for shortest duration given potential for neonatal adverse effects (e.g., thrombocytopenia, renal dysfunction).
Increased clearance and volume of distribution in pregnancy may reduce serum levels; consider dose increase by 20-30% if inadequate analgesia. Avoid in third trimester near delivery due to risk of neonatal respiratory depression. Use lowest effective dose for shortest duration.
No standard dose adjustments recommended; however, due to increased plasma volume and metabolism in pregnancy, higher doses may be required to achieve therapeutic effect. Avoid near term.
Tramadol is a prodrug requiring CYP2D6 metabolism to its active metabolite M1 for analgesic effect. Poor metabolizers (7-10% of population) may experience reduced efficacy. Caution with serotonergic drugs due to risk of serotonin syndrome. Seizure risk increased in patients with epilepsy, history of seizures, or concomitant use of SSRIs, SNRIs, tricyclic antidepressants, or other drugs that lower seizure threshold. Dose adjustment needed in renal impairment (Cr Cl <30 m L/min: extended interval or avoid) and hepatic cirrhosis (reduce dose or extend interval). Avoid use in patients with severe hepatic impairment. Not recommended for children <12 years, or <18 years for tonsillectomy/adenoidectomy. Maximum single dose: 100 mg; maximum daily dose: 400 mg (300 mg in patients >75 years). Onset of action: 30-60 minutes; peak effect: 2-3 hours; duration: 4-6 hours.
ACEPHEN (acetaminophen) is commonly used for mild to moderate pain and fever. Avoid exceeding 4 g/day in adults to prevent hepatotoxicity. In patients with hepatic impairment, reduce maximum daily dose to 2 g. Consider acetylcysteine for overdose. Onset of action is 15-30 minutes orally.
Take exactly as prescribed; do not increase dose or frequency without consulting your doctor.,Do not crush or chew extended-release tablets; swallow whole.,Avoid alcohol and other CNS depressants (e.g., benzodiazepines, sedatives) as they increase risk of severe drowsiness, respiratory depression, and overdose.,Tramadol may cause dizziness or drowsiness; avoid driving or operating machinery until you know how it affects you.,Do not stop abruptly; withdrawal symptoms (anxiety, sweating, insomnia, pain) may occur. Taper under medical supervision.,Report symptoms of serotonin syndrome (agitation, hallucinations, rapid heart rate, fever, muscle stiffness, twitching, nausea, diarrhea) immediately.,Seek emergency help if you experience slow/shallow breathing, severe drowsiness, or difficulty waking up.,Dispose of unused tramadol properly via drug take-back programs to prevent accidental ingestion or misuse.,Inform your doctor of all medications you take, especially antidepressants, antipsychotics, and pain relievers.,Pregnancy: avoid during labor; prolonged use may cause neonatal withdrawal syndrome. Breastfeeding: not recommended.,Grapefruit juice has not been shown to interact significantly, but avoid excessive intake.
Do not exceed 4000 mg (4 grams) in 24 hours.,Avoid drinking alcohol while taking this medication.,Do not combine with other products containing acetaminophen.,Take with food if stomach upset occurs.,Seek immediate medical help if you experience symptoms of liver damage: yellowing of skin/eyes, dark urine, severe abdominal pain.
"Concomitant use of tramadol and secobarbital increases the risk of severe adverse effects, including profound sedation, respiratory depression, coma, and death. This is due to additive central nervous system depression from both drugs. Patients should be closely monitored for signs of respiratory depression and excessive sedation."
"Coadministration of tramadol, a weak mu-opioid receptor agonist and serotonin-norepinephrine reuptake inhibitor (SNRI), with pargyline, a nonselective monoamine oxidase inhibitor (MAOI), poses a significant risk of serotonin syndrome. This potentially life-threatening condition results from excessive serotonergic activity in the central nervous system, manifesting as altered mental status, autonomic instability, and neuromuscular hyperactivity. Additionally, tramadol's metabolism via CYP2D6 to its active metabolite M1, and use with an MAOI may lead to hypertensive crisis due to enhanced noradrenergic effects."
"Lisuride, a dopamine agonist, and tramadol, an opioid analgesic with serotonergic activity, synergistically increase the risk of serotonin syndrome, a potentially life-threatening condition characterized by altered mental status, autonomic instability, and neuromuscular hyperactivity. The combination may also potentiate CNS depression, leading to excessive sedation, respiratory depression, and impaired psychomotor function. Concurrent use should be avoided or undertaken with extreme caution due to the heightened risk of serious adverse outcomes."
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about Tramadol vs ACEPHEN, answered by our medical review team.
Tramadol is a Opioid Agonist that works by Tramadol is a centrally acting synthetic opioid analgesic that binds to μ-opioid receptors and inhibits the reuptake of norepinephrine and serotonin, modulating pain transmission.. ACEPHEN is a Non-Opioid Analgesic that works by ACEPHEN (acetaminophen) is a para-aminophenol derivative with analgesic and antipyretic activity. Its mechanism involves inhibition of cyclooxygenase (COX) enzymes in the central nervous system, particularly COX-2, reducing prostaglandin synthesis. It has weak peripheral COX inhibition and minimal anti-inflammatory effect.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between Tramadol and ACEPHEN depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of Tramadol is: 50-100 mg orally every 4-6 hours as needed for pain; maximum 400 mg/day. For moderate to severe pain, 50-100 mg IV or IM every 4-6 hours; maximum 600 mg/day.. The standard adult dose of ACEPHEN is: 325-650 mg orally every 4-6 hours as needed; maximum 4 g/day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between Tramadol and ACEPHEN in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. Tramadol is classified as Category D/X. First trimester: Limited human data; animal studies show no clear teratogenicity at therapeutic doses but increased risk of neural tube defects at high doses. Second and third trim. ACEPHEN is classified as Category C. Pregnancy Category C. First trimester: potential risk of neural tube defects and orofacial clefts (limited human data, animal studies show embryotoxicity). Second and third trimest. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.